Pfizer Inc. (PFE)

From the record

Pfizer Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Pfizer Inc.'s 6 filed years say what it did: revenue went from $42 billion in fiscal 2020 to $63 billion in fiscal 2025, up 8.5% a year; it rose in 3 of 5 years; the deepest fall was 41% from fiscal 2022 to fiscal 2023; net income was positive in 6 of 6 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Pfizer Inc.'s diluted share count shrank about 0.1% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 2 sales and 3 purchases of their own stock on the open market in the year to 2026-11-03, buying about $3 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Pfizer Inc. earned about 9 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 22 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 58 cents per dollar of assets, and net share issuance: its share count grew 0.2% over the year (the filed statements).

From the record

Pfizer Inc.'s standing among 315 graded names in its industry family: revenue of $63 billion in fiscal 2025 ranks in the top 1% by size; a net margin of 12.4% ranks in the top 16%; revenue growth of -14.8% a year over the last 3 filed years ranks in the bottom 23% (its annual reports).

From the record

Pfizer Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Bourla, Albert (Chairman & CEO, as filed), filing under that title since 2019-01-02, 7.9 years (top 24% of its family); the 24 officers and directors filing in the last fifteen months have been on the record a median of 6.6 years (top 32%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 24 people in charge now (top 29%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Pfizer Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $1.1 billion against debt of $62 billion leaves -29.1% of its assets as net cash, bottom 4% of its family; cash from operations less capital spending is 14.5% of revenue (top 17%); a gross margin of 74.3% (top 43%); research spending of 16.7% of revenue (bottom 21%) (its annual report).

From the record

Pfizer Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -14.8% a year over the last three filed years against 8.5% over all 6, slowing (bottom 24% of its family); the newest year grew -1.6% (bottom 35%); research spending grew -3% a year (bottom 43%); capital spending grew -6.7% a year (top 45%) (its annual reports). Pfizer Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Pfizer Inc.'s newest year against its own record: revenue of $63 billion in fiscal 2025 came in 24% above the $50 billion its prior three years' pace pointed to (top 25% of its family); net income of $7.8 billion against a prior three-year average of $14 billion (bottom 27%); a net margin of 12.4% against 15.7% before (bottom 33%) (its annual reports).